Grifols, S.A. (NASDAQ: GRFS) Stock Competitors & Peer Comparison
See GRFS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GRFS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRFS | $8.43 | -0.35% | 7.1B | 9.69 | $0.87 | +3.34% |
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
GRFS vs LLY Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while LLY trades at $1,354.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas LLY's P/E ratio is 43.57. In terms of profitability, GRFS's ROE is +0.09%, compared to LLY's ROE of +0.84%. Regarding short-term risk, GRFS is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
GRFS vs JNJ Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas JNJ's P/E ratio is 25.74. In terms of profitability, GRFS's ROE is +0.09%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, GRFS is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
GRFS vs ABBV Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas ABBV's P/E ratio is 28.59. In terms of profitability, GRFS's ROE is +0.09%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, GRFS is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
GRFS vs MRK Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, MRK has a market cap of 362B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas MRK's P/E ratio is 45.70. In terms of profitability, GRFS's ROE is +0.09%, compared to MRK's ROE of +0.05%. Regarding short-term risk, GRFS is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check MRK's competition here
Novartis AG (NYSE: NVS)
GRFS vs NVS Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, NVS has a market cap of 307B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas NVS's P/E ratio is 18.71. In terms of profitability, GRFS's ROE is +0.09%, compared to NVS's ROE of +0.25%. Regarding short-term risk, GRFS is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
GRFS vs AZN Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas AZN's P/E ratio is 20.13. In terms of profitability, GRFS's ROE is +0.09%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GRFS is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
GRFS vs AMGN Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while AMGN trades at $460.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas AMGN's P/E ratio is 20.57. In terms of profitability, GRFS's ROE is +0.09%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, GRFS is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
GRFS vs GILD Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas GILD's P/E ratio is -427.74. In terms of profitability, GRFS's ROE is +0.09%, compared to GILD's ROE of -0.22%. Regarding short-term risk, GRFS is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
GRFS vs NVO Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas NVO's P/E ratio is 10.03. In terms of profitability, GRFS's ROE is +0.09%, compared to NVO's ROE of +0.54%. Regarding short-term risk, GRFS is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
GRFS vs PFE Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas PFE's P/E ratio is 9.63. In terms of profitability, GRFS's ROE is +0.09%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GRFS is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
GRFS vs BMY Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while BMY trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas BMY's P/E ratio is 10.48. In terms of profitability, GRFS's ROE is +0.09%, compared to BMY's ROE of +0.44%. Regarding short-term risk, GRFS is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check BMY's competition here
Sanofi (NASDAQ: SNY)
GRFS vs SNY Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while SNY trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas SNY's P/E ratio is 10.24. In terms of profitability, GRFS's ROE is +0.09%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GRFS is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check SNY's competition here
GSK plc (NYSE: GSK)
GRFS vs GSK Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas GSK's P/E ratio is 10.87. In terms of profitability, GRFS's ROE is +0.09%, compared to GSK's ROE of +0.23%. Regarding short-term risk, GRFS is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
GRFS vs CELG-RI Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.09%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, GRFS is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
GRFS vs BIIB Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas BIIB's P/E ratio is 15.69. In terms of profitability, GRFS's ROE is +0.09%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, GRFS is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
GRFS vs HZNP Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GRFS's ROE is +0.09%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GRFS is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check HZNP's competition here
Organon & Co. (NYSE: OGN)
GRFS vs OGN Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas OGN's P/E ratio is 4.13. In terms of profitability, GRFS's ROE is +0.09%, compared to OGN's ROE of +0.22%. Regarding short-term risk, GRFS is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GRFS.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
GRFS vs AMRN Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while AMRN trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas AMRN's P/E ratio is -116.55. In terms of profitability, GRFS's ROE is +0.09%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, GRFS is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
GRFS vs MIRA Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas MIRA's P/E ratio is -0.38. In terms of profitability, GRFS's ROE is +0.09%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, GRFS is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
GRFS vs SCLX Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas SCLX's P/E ratio is -0.04. In terms of profitability, GRFS's ROE is +0.09%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GRFS is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
GRFS vs SCLXW Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.09%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GRFS is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
GRFS vs BDSIW Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GRFS's ROE is +0.09%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GRFS is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
GRFS vs CRXT Comparison November 2026
Grifols, S.A. (NASDAQ: GRFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 7.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GRFS is priced at $8.43 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 9.69, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GRFS's ROE is +0.09%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GRFS is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GRFS.Check CRXT's competition here